Alembic, LLC appears in FDA device records as the applicant behind a small set of percutaneous catheter clearances. The supplied collection holds one 510(k) record, K261938 for the APRO 88 Catheter, with a substantially equivalent decision dated October 6, 2026. Earlier filings in the numbered sources cover the APRO 55 Swift Catheter with Alembic Aspiration Tubing and the APRO 55 Intermediate Catheter, both cleared in 2025. Company background comes from Alembic's own website, which describes a privately held medical device incubator founded in 2012 by Dr. Aaron Berez and focused on neurovascular products. [1][4][7]
The APRO 88 clearance
K261938 covers the APRO 88 Catheter under product code QJP, device name Catheter, Percutaneous, Neurovasculature, regulation 21 CFR 870.1250, Class II. The FDA record lists Alembic, LLC as applicant at 627 National Ave., Mountain View, CA, with a date received of June 10, 2026 and a decision date of October 6, 2026. The decision code is SESE, described as Substantially Equivalent, under a Traditional submission with a summary statement. The advisory committee is Cardiovascular, while the review advisory committee is listed as Neurology. [1]
A separate FDA database page for the same submission lists the panel as Neurology, the type as Traditional, no third-party review, no combination product, and no authorized predetermined change control plan. Innolitics reproduces the record with the same identifiers: K261938, Alembic, LLC, product code QJP, decision SESE, decision date October 6, 2026, regulation 21 CFR 870.1250. [2][6]
Earlier APRO 55 filings
An April 28, 2025 FDA clearance letter for K250958 names the APRO 55 Swift Catheter and Alembic Aspiration Tubing, regulation 21 CFR 870.1250, Class II, product code NRY, received March 31, 2025. The accompanying summary lists the common name Catheter, Thrombus Retriever, and the applicant contact as Lisa Yen, identified as Vice President of Regulatory and Quality. [7]
An April 29, 2025 letter for K250962 covers the APRO 55 Intermediate Catheter under the same regulation, Class II, with product codes DQY and QJP, received March 31, 2025. Its summary gives the common name percutaneous catheter and the same applicant address and contact details. These two 2025 filings are not part of the supplied collection snapshot; they appear only in the numbered sources. [8]
Company background as published
Alembic's own About page states the company is located in Mountain View, California, was founded in 2012 by Dr. Aaron Berez, and is a privately held medical device incubator focused on bringing neurovascular solutions to market. The same page describes Cathera, Inc. as the first Alembic portfolio company, developer of the Phenom family of microcatheters, acquired by Medtronic in 2018, and Palmera, Inc. as a second portfolio company working on stroke treatment products. These are the publisher's characterizations, not independently verified ownership facts. [4]
The company homepage carries the line "Bringing Novel Neurovascular Solutions to Market" and lists 627 National Avenue, Mountain View, CA 94043, the same street address that appears in the FDA filings. That address is a filing and contact address in the sources; the sources do not establish it as a headquarters. No customer relationships, certifications, commercial availability or clinical performance data appear in the public information. [5][1]
What the snapshot does and does not show
The supplied portfolio snapshot, retrieved November 20, 2026, contains one linked record, K261938, on the 510(k) pathway, with a decision count of one SESE. That single-record sample is the whole of the snapshot, so it cannot be read as total company sales, total portfolio or safety performance. The 2025 APRO 55 clearances sit outside the snapshot and are documented only through their FDA letters and summaries. [1][7][8]

